NCT04276935

Brief Summary

This trial develops a health-related symptom index for participants with and either treated or monitored for anal high-grade squamous intraepithelial lesions. The health-related quality of life index may help to capture the symptoms and related experiences of living with or being treated for high-grade squamous intraepithelial lesions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2018

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 6, 2018

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

January 22, 2019

Completed
1.1 years until next milestone

First Posted

Study publicly available on registry

February 19, 2020

Completed
11 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2020

Completed
3.7 years until next milestone

Results Posted

Study results publicly available

November 18, 2023

Completed
Last Updated

March 7, 2025

Status Verified

March 1, 2025

Enrollment Period

1.3 years

First QC Date

January 22, 2019

Results QC Date

June 30, 2022

Last Update Submit

March 5, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Development of Spanish-language Version of the Anal Cancer/High-grade Squamous Intraepithelial Lesions (HSIL) Outcomes Research (ANCHOR) Health-related Quality of Life (HRQoL) Index-Round 1 and Round 2

    Participants completed A-HRSI, as aurally administered over telephone to indicate whether there were any items or aspects of the instructions that were difficult to understand, and then complete a process of retrospective probing. Summary reports from the Round 1 interview were coded to highlight any instances where a participant indicated that they experienced difficulty with an item or concept within an item. For any item that was reported by at least three participants as difficult for any reason, that item or concept was reviewed to determine whether the difficulty was due to (1) the concept being measured or (2) a translation issue (i.e., register, jargon, or regionalism). These items were revised during a research team panel discussion and used in Round 2 interviews with additional eligible participants. A similar process was used for Round 2.

    45-60 minutes during the telephone call in each round.

Study Arms (1)

Health Services Research (cognitive interviews)

Participants take part in cognitive interviews in Spanish over 45-60 minutes.

Other: InterviewOther: Quality-of-Life AssessmentOther: Questionnaire Administration

Interventions

Participate in cognitive interview

Health Services Research (cognitive interviews)

Ancillary studies

Also known as: Quality of Life Assessment
Health Services Research (cognitive interviews)

Ancillary studies

Health Services Research (cognitive interviews)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

HIV-infected adult men and women with biopsy-proven anal HSIL that was treated in the last 9 months, and who are fluent in Spanish with limited English proficiency.

You may qualify if:

  • Human immunodeficiency virus (HIV)-1 infection.
  • Biopsy-proven anal HSIL within the prior nine months.
  • Participant must have received anal HSIL treatment in the last nine months. If the participant's treatment plan is observation? the participant must have been diagnosed with anal HSIL in the last nine months.
  • Life expectancy of greater than 5 years.
  • Fluent in Spanish with limited English proficiency, per self-report.

You may not qualify if:

  • History of anal cancer.
  • Inability to understand a written consent form.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

University of California - San Francisco

San Francisco, California, 94143, United States

Location

Jackson Memorial Hospital

Miami, Florida, 33136, United States

Location

Anal Dysplasia Clinic MidWest

Chicago, Illinois, 60614, United States

Location

Virginia Mason Medical Center

Seattle, Washington, 98101, United States

Location

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Interventions

Interviews as Topic

Condition Hierarchy (Ancestors)

HIV InfectionsBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesSlow Virus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Results Point of Contact

Title
Dr. Thomas M. Atkinson
Organization
Memorial Sloan Kettering Cancer Center

Study Officials

  • Thomas Atkinson

    AIDS Malignancy Consortium

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 22, 2019

First Posted

February 19, 2020

Study Start

November 6, 2018

Primary Completion

March 1, 2020

Study Completion

March 1, 2020

Last Updated

March 7, 2025

Results First Posted

November 18, 2023

Record last verified: 2025-03

Locations